21M shares is ~5% of IPIX shares. That's a rounding error for Gilead.
If IPIX goes to $5 that's $105M. That's less than 4% of Remdesivir's 2020 earnings.
If IPIX goes to $50 that's ~$1B or about 1.2% of Gilead's $83B market cap.
No, I don't think Gilead has anything to do with Kips Bay. If the phase 2 COVID trial goes well they will buy it for one or two or three billion.
Big pharma doesn't buy shares in OTC penny stocks. If they want them, they just acquire them in much the same way I would buy a pair of shoes at Macy's.
“Did Gilead create an alias to allow for a significant buy-in with IPIX (for Brilacidin) that could be used synergistically with remdesivir in the not-too-distant future?”
No. And there are roughly a million reasons (I exaggerate slightly but not much) why that is a ludicrous fantasy.